ArticleeLife2021
Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 168 citations in OpenAlex.
- Treatment with Sulodexide Downregulates Biomarkers for Endothelial Dysfunction in Convalescent COVID-19 Patients.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisTrial
- Microvascular remodeling and endothelial dysfunction across the post-COVID-19 spectrum: a prospective observational case-control study.BMC medicine · 2026Observational
- Translational insights into Long-COVID: evaluation of preclinical animal models along the lung-brain-immune axis with focus on Golden Syrian Hamsters.Journal of neuroinflammation · 2026Review
- Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome.International journal of cardiology. Heart & vasculature · 2026Article
- Exploratory Analysis of Coagulation and Fibrinolysis Trajectories After IL-6 Antagonist Therapy in COVID-19: A Case Series.Biomedicines · 2026Article
- CD169Frontiers in cellular and infection microbiology · 2026Article
- C3d Complement Activation and Antibody Immunity in Convalescent COVID-19: Insights From Adults and Children.Journal of immunology research · 2026Article
- Unraveling the cardiovascular burden of long COVID: symptom profiles, underlying mechanisms, and clinical management insights.Frontiers in cardiovascular medicine · 2026Review
- COVID-19-associated neurological and psychological manifestations.Nature reviews. Disease primers · 2025Review
- Risk of Sequelae Following COVID-19 Infection: A Nationwide Study Focusing on Risk Factors and Long-Term Impacts.Journal of clinical medicine · 2025Article
- Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects.International journal of molecular sciences · 2025Article
- Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS.Critical care (London, England) · 2025Article
- Effects of Cytokines (or Activating Factors) on Arterial Endothelial Cells.International journal of molecular sciences · 2025Review
- Sustained Lung Inflammation Post-SARS-CoV-2 Infection in Mice Is Associated with Increased Pulmonary T Cells.European journal of immunology · 2025Article
- Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial Cells.Inflammation · 2025Article
- Association between pre-existing cardiovascular risk factors and post-acute sequelae of COVID-19 in older adults.Anales del sistema sanitario de Navarra · 2025Article
- Potential Biomarkers for Predicting the Risk of Developing Into Long COVID After COVID-19 Infection.Immunity, inflammation and disease · 2025Article
- Exploring the landscape of symptom-specific inflammatory cytokines in post-COVID syndrome patients.BMC infectious diseases · 2024Article
- Endothelial dysfunction and cardiovascular risk in post-COVID-19 patients after 6- and 12-months SARS-CoV-2 infection.Infection · 2024Article
- COVID-19 in the Initiation and Progression of Atherosclerosis: Pathophysiology During and Beyond the Acute Phase.JACC. Advances · 2024Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 4 countries.
Funding
Abstract
Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.